Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masahiko Ayaki

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Plos One|October 20, 2022
The ocular symptoms and signs during the COVID-19 pandemicMasahiko Ayaki, Kazuno Negishi
Biomed Research International|February 7, 2022
Short Tear Breakup Time Could Exacerbate the Progression of Presbyopia in WomenMasahiko Ayaki, Kazuno Negishi
Clinical Ophthalmology (Auckland, N.Z.)|September 9, 2010
Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell linesMasahiko Ayaki, Atsuo Iwasawa
Scientific Reports|April 28, 2022
Decrease of tear break-up time at Japanese eye clinics during five consecutive yearsMasahiko Ayaki, Kazuno Negishi
Biocontrol Science|September 28, 2011
Cell viability of four corneoconjunctival cell lines exposed to five preservatives and a surfactant used for infection control in eyedropsMasahiko Ayaki, Atsuo Iwasawa
Plos One|November 11, 2021
Presbyopia developed earlier during the COVID-19 pandemicKazuno Negishi, Masahiko Ayaki
Clinical Ophthalmology (Auckland, N.Z.)|December 18, 2023
Seasonality of Tear Meniscus Volume and Dry Eye-Related Symptoms - A Cross-Sectional Retrospective Cohort StudyMasahiko Ayaki, Kazuno Negishi
Journal of Clinical Medicine|October 16, 2024
Near Add Power of Glaucoma Patients with Early PresbyopiaMasahiko Ayaki, Kazuo Ichikawa
Japanese Journal of Ophthalmology|August 11, 2011
Cytotoxicity assays of new artificial tears containing 2-methacryloyloxyethyl phosphorylcholine polymer for ocular surface cellsMasahiko Ayaki, Atsuo Iwasawa, Yoshimi Niwano
Biocontrol Science|September 26, 2012
Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chlorideMasahiko Ayaki, Atsuo Iwasawa, Yoshimi Niwano
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Plos One|October 20, 2022
The ocular symptoms and signs during the COVID-19 pandemicMasahiko Ayaki, Kazuno Negishi
Biomed Research International|February 7, 2022
Short Tear Breakup Time Could Exacerbate the Progression of Presbyopia in WomenMasahiko Ayaki, Kazuno Negishi
Clinical Ophthalmology (Auckland, N.Z.)|September 9, 2010
Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell linesMasahiko Ayaki, Atsuo Iwasawa
Scientific Reports|April 28, 2022
Decrease of tear break-up time at Japanese eye clinics during five consecutive yearsMasahiko Ayaki, Kazuno Negishi
Biocontrol Science|September 28, 2011
Cell viability of four corneoconjunctival cell lines exposed to five preservatives and a surfactant used for infection control in eyedropsMasahiko Ayaki, Atsuo Iwasawa
Plos One|November 11, 2021
Presbyopia developed earlier during the COVID-19 pandemicKazuno Negishi, Masahiko Ayaki
Clinical Ophthalmology (Auckland, N.Z.)|December 18, 2023
Seasonality of Tear Meniscus Volume and Dry Eye-Related Symptoms - A Cross-Sectional Retrospective Cohort StudyMasahiko Ayaki, Kazuno Negishi
Journal of Clinical Medicine|October 16, 2024
Near Add Power of Glaucoma Patients with Early PresbyopiaMasahiko Ayaki, Kazuo Ichikawa
Japanese Journal of Ophthalmology|August 11, 2011
Cytotoxicity assays of new artificial tears containing 2-methacryloyloxyethyl phosphorylcholine polymer for ocular surface cellsMasahiko Ayaki, Atsuo Iwasawa, Yoshimi Niwano
Biocontrol Science|September 26, 2012
Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chlorideMasahiko Ayaki, Atsuo Iwasawa, Yoshimi Niwano
Pageof 11